Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 7:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 747 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glaucoma Clear all
Not listed Phase 2 Interventional Accepts healthy volunteers

Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine Therapy

NCT01345448
View directory record Official record
Conditions
Glaucoma
Interventions
Brimonidine, Placebo Lotion
Drug
Lead sponsor
Nanduri, Padma, M.D., FACS
Individual
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Visalia, California
Source: ClinicalTrials.gov public record
Updated May 1, 2011 · Synced Sep 6, 2026, 7:28 AM EDT
Terminated Phase 4 Interventional

A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Shunt to Trabeculectomy

NCT00597181
View directory record Official record
Conditions
Glaucoma
Interventions
Trabeculectomy with mitomycin c, Ex-Press mini shunt with mitomycin c
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Sep 6, 2026, 7:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adult Providing Access to the Visual Environment (PAVE) - Glaucoma Pilot

NCT00338208
View directory record Official record
Conditions
Glaucoma
Interventions
Training in the Use of Low Vision Devices
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Sep 6, 2026, 7:28 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension

NCT00945958
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
SPARC0913
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Sep 6, 2026, 7:28 AM EDT
Completed Not applicable Interventional Results available

SENSIMED Triggerfish Safety and Tolerability

NCT01319617
View directory record Official record
Conditions
Glaucoma
Interventions
SENSIMED Triggerfish
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2013 · Synced Sep 6, 2026, 7:28 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Instrument for Glaucoma Early Detection and Monitoring

NCT00578110
View directory record Official record
Conditions
Glaucoma
Interventions
Glaucoma Diagnosis, Name: Neucodia
Device
Lead sponsor
Synabridge Corporation
Industry
Eligibility
40 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
5
States / cities
Birmingham, Alabama • New Haven, Connecticut • Raritan, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Sep 6, 2026, 7:28 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

NCT07209410
View directory record Official record
Conditions
Glaucoma
Interventions
Brimonidine Tartrate Ophthalmic 0.025%
Drug
Lead sponsor
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 6, 2026, 7:28 AM EDT
Completed Phase 4 Interventional

Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension

NCT00300079
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
brinzolamide 1.0%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 6, 2026, 7:28 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma

NCT02855450
View directory record Official record
Conditions
Glaucoma
Interventions
rhNGF, Vehicle
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 6, 2026, 7:28 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Optic Nerve Head Strain as Biomarker for Glaucoma

NCT06240312
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Images of eye at 2 eye pressures
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 6, 2026, 7:28 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Retinal Blood Flow and Autoregulation

NCT05344274
View directory record Official record
Conditions
Glaucoma
Interventions
Indocyanine Green Angiography, Isocapnic Oxygen, Ocular Imaging with Optical Coherence Tomography (OCT) and Adaptive Optics (AO)
Diagnostic Test · Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 6, 2026, 7:28 AM EDT
Not listed Phase 3 Interventional

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

NCT05165290
View directory record Official record
Conditions
Elevated Intraocular Pressure
Interventions
Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%
Drug
Lead sponsor
TearClear Corp
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Garden Grove, California • Glendale, California • Mission Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Sep 6, 2026, 7:28 AM EDT
Recruiting Not applicable Interventional

Electrical Stimulation for the Treatment of Optic Neuropathies

NCT05626426
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open-Angle, Optic Nerve Diseases
Interventions
Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 6, 2026, 7:28 AM EDT
Not listed No phase listed Observational

iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study

NCT04624685
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Not listed
Lead sponsor
Glaukos Corporation
Industry
Eligibility
Not listed
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
24
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Santa Rosa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Sep 6, 2026, 7:28 AM EDT
Completed Phase 3 Interventional

SOLX Titanium Sapphire Laser for Trabeculoplasty

NCT00145535
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open Angle
Interventions
SOLX Titanium Sapphire Laser (TiSaLT), Argon Laser Trabeculoplasty (ALT)
Device
Lead sponsor
SOLX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
5
States / cities
Petaluma, California • Tampa, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2010 · Synced Sep 6, 2026, 7:28 AM EDT
Terminated Not applicable Interventional Results available

Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

NCT01828255
View directory record Official record
Conditions
Primary Open-angle Glaucoma (POAG) Patient
Interventions
SENSIMED Triggerfish®
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
40 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 6, 2026, 7:28 AM EDT
Completed Not applicable Interventional Results available

Shunt Tube Exposure Prevention Study

NCT01551550
View directory record Official record
Conditions
Glaucoma
Interventions
GDD, Amniotic Membrane Graft, Pericardial Graft
Procedure
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
21 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
4
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Sep 6, 2026, 7:28 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Observational Study of How Patients Take Eye Drops

NCT00750646
View directory record Official record
Conditions
Glaucoma
Interventions
MEMS cap
Device
Lead sponsor
Robin, Alan L., M.D.
Individual
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2008 · Synced Sep 6, 2026, 7:28 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

NCT06369077
View directory record Official record
Conditions
Glaucoma, Open-Angle, Glaucoma; Drugs
Interventions
dorzolamide/timolol
Drug
Lead sponsor
CT Glaucoma Associates
Other
Eligibility
25 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Norwalk, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 6, 2026, 7:28 AM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01215786
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo), timolol ophthalmic solution 0.5%, AGN-207281 vehicle ophthalmic solution (Placebo)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2015 · Synced Sep 6, 2026, 7:28 AM EDT
Completed Not applicable Interventional

Effect of Intra-subject Phaco/Trabectome vs. Phaco/Kahook Dual Blade on Intraocular Pressure

NCT03894631
View directory record Official record
Conditions
Glaucoma
Interventions
KDB/Phacoemulsification, Trabectome/Phacoemulsification
Procedure
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 95 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 6, 2026, 7:28 AM EDT
Completed No phase listed Observational

Survey of Patients Taking IOP-Lowering Eye Drops

NCT02384772
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Survey
Other
Lead sponsor
ForSight Vision5, Inc.
Industry
Eligibility
Not listed
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Sep 6, 2026, 7:28 AM EDT
Completed Not applicable Interventional Results available

The AVB Study: Prospective Study Comparing the Ahmed Valve and the Baerveldt Implant for Treating Refractory Glaucoma

NCT00940823
View directory record Official record
Conditions
Glaucoma
Interventions
Ahmed FP7 Valve, Baerveldt-350 Tube
Device
Lead sponsor
Credit Valley EyeCare
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
3
States / cities
Indianapolis, Indiana • Nashville, Tennessee • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 6, 2026, 7:28 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a Drug Delivery System in Glaucoma

NCT01016691
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 6, 2026, 7:28 AM EDT